Medicare GLP-1 Bridge in 2026: Eligibility, Cost, and How It Works

Medicare GLP-1 Bridge at a glance

The Bridge is nationwide, including U.S. states and territories, but not every Medicare beneficiary or every Medicare plan type qualifies.

Who may qualify for the Medicare GLP-1 Bridge?

A beneficiary must have eligible Medicare drug coverage, be at least 18 years old, use the requested medication to reduce excess body weight or maintain weight reduction, and meet one of the current CMS clinical pathways.

CMS requires the provider to attest that the medication is being used with current and ongoing lifestyle modification, including structured nutrition and physical activity consistent with the applicable FDA-approved label.

Current clinical pathways

These criteria are not a recommendation to begin or continue treatment. A licensed clinician must determine whether a medication is appropriate and whether the Bridge requirements are met.

Which BMI does Medicare use?

CMS says eligibility is based on the beneficiary’s BMI when GLP-1 therapy was initiated, not necessarily the BMI on the date of the Bridge prior-authorization request.

That means a person who started therapy before July 1, 2026 may still be evaluated using the BMI documented at treatment initiation. The provider must be able to attest that the applicable requirement was met at that time.

Do not assume that a current BMI below a threshold automatically makes someone ineligible, or that a prior BMI automatically qualifies them. The provider and the Bridge processor determine what documentation and attestation apply.

Which Medicare plan types may participate?

CMS currently lists these eligible coverage types:

• A standalone Medicare prescription drug plan, or PDP.
• A coordinated-care Medicare Advantage plan with drug coverage, including certain HMO, HMOPOS, and local or regional PPO plans.
• A Special Needs Plan.
• An employer or union group waiver plan.
• The Limited Income Newly Eligible Transition program.

Some other arrangements are not eligible unless the beneficiary also has a qualifying standalone Part D plan. Examples currently listed by CMS include private fee-for-service plans, certain cost plans, PACE organizations, fallback plans, and religious fraternal benefit plans.

Plan structures can be difficult to identify from a member card alone. Call 1-800-MEDICARE (1-800-633-4227) or use the official Medicare eligibility tool when the plan type is unclear.

Which medications are included?

As of August 6, 2026, CMS lists the following products when prescribed for the Bridge’s covered weight-management use:

The single-dose Zepbound vial and single-dose pen are not currently included. CMS also says pen needles for the Zepbound KwikPen are not covered by the Bridge and may need to be purchased separately.

Product lists and National Drug Codes can change. Verify the exact brand, formulation, strength, and pharmacy claim route before relying on coverage.

For medication-specific cost and access details, review the separate Foundayo pill guide and Wegovy pill guide.

How the $50 copay works

An eligible beneficiary pays a $50 copay for a monthly supply when an included medication is approved and processed through the Medicare GLP-1 Bridge.

Because the Bridge operates outside the normal Part D benefit payment flow:

• The Part D deductible does not apply to the Bridge claim.
• The $50 copay does not count toward Part D true out-of-pocket costs.
• Extra Help or another low-income subsidy does not reduce the $50 copay.
• The Medicare Prescription Payment Plan cannot spread the Bridge copay across multiple months.
• Manufacturer coupons and discount programs cannot be applied to a Bridge claim.
• The Bridge claim may not appear in the same way as a normal Part D claim on plan documents.

The $50 amount applies to the covered medication claim. It does not necessarily include unrelated clinician visits, tests, supplies, or services that a provider may recommend.

Is there a Medicare GLP-1 Bridge application?

There is no separate consumer application that a beneficiary completes alone.

The current process generally works like this:

1. The beneficiary talks with a health care provider. The provider evaluates whether a covered medication and the Bridge pathway may be appropriate.
2. The provider sends a prescription to the pharmacy. The prescription must be for an included product and a use covered by the demonstration.
3. The pharmacy attempts to process the claim. When prior authorization is required, the request is routed to the prescriber electronically or by fax.
4. The provider completes prior authorization. The provider attests that the beneficiary meets the current criteria and that the medication is being prescribed for the covered weight-management use.
5. The Bridge processor issues a decision. CMS says the approval or denial is generally sent within 72 hours after a completed submission.
6. The pharmacy fills the prescription after approval. The beneficiary should receive a mailed notice confirming Bridge coverage.

CMS says a Part D denial is not required before a potentially eligible prescription is routed to the Bridge.

How long does prior authorization last?

CMS currently says an approved Bridge prior authorization remains valid through December 31, 2027, including refills and dose changes.

A new prior authorization is generally required when the beneficiary switches from one covered GLP-1 drug to another. The approval also does not override the prescriber’s responsibility to monitor treatment and determine whether continuing the medication remains appropriate.

When Part D may apply instead

The Bridge was designed for covered GLP-1 drugs used to reduce excess body weight or maintain weight reduction. Some GLP-1 uses can already be covered under the basic Part D benefit.

CMS currently says a prescription should remain in the Part D pathway when it is being used for a Part D-coverable indication, including certain uses involving:

• Type 2 diabetes.
• Moderate-to-severe obstructive sleep apnea.
• Noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis.
• Reduction of major adverse cardiovascular events when the prescription is for that indication.

A beneficiary is not moved into the Bridge simply because the Part D plan denies or does not list a GLP-1 for one of those Part D-coverable uses. Existing Part D formulary-exception and appeal processes may still apply.

What if Medicare Part D already paid for a GLP-1?

Medicare.gov says a beneficiary who already receives a GLP-1 through Medicare drug coverage is not eligible for the Bridge and should continue through the current Part D pathway.

CMS says that, for 2026, it reviews Part D utilization during calendar year 2026. The agency has not yet established the relevant lookback period for 2027.

This rule is operational and may be updated. A beneficiary with prior Part D GLP-1 claims should call 1-800-MEDICARE and ask the pharmacy or prescriber to confirm the current routing rule.

Can a telehealth provider help with the Bridge?

A telehealth service may be able to help only when a licensed clinician can evaluate the patient, prescribe an included product when appropriate, and complete the Medicare GLP-1 Bridge prior authorization.

Before paying a telehealth fee, ask:

• Does the service work with Medicare beneficiaries in the consumer’s state?
• Will the clinician review the Bridge eligibility criteria?
• Does the service complete the Bridge prior-authorization form or electronic request?
• Which pharmacy will receive the prescription?
• Is any membership or consultation fee separate from the medication copay?
• What happens financially if the clinician does not prescribe or the Bridge denies authorization?
• Will the service help route a Part D-coverable use through the Part D plan instead?

A telehealth membership does not create Bridge eligibility, guarantee a prescription, or guarantee prior-authorization approval.

What happens after a denial?

CMS says the Medicare GLP-1 Bridge itself does not have a formal appeal process.

A provider may resubmit the prior-authorization form when the original submission contained incorrect information or when updated or additional information is available. That is different from the appeal rights that may apply to a separate Part D coverage decision.

Ask the provider or pharmacy to identify the exact reason for the denial before paying for another consultation or changing prescription pathways.

Questions to ask before relying on the Bridge

1. Is the Medicare drug coverage type eligible for the Bridge?
2. Is the medication being prescribed for the Bridge’s covered weight-management use?
3. Which BMI and medical-history records support the prior authorization?
4. Has Medicare Part D already paid for a GLP-1 during the relevant lookback period?
5. Is the exact drug and formulation included?
6. Who will submit the prior authorization?
7. Has the pharmacy routed the claim to the Bridge processor?
8. When should the provider expect the authorization request?
9. What costs exist beyond the $50 medication copay?
10. What happens if the authorization is denied?
11. Would a Part D-covered indication require a different route?
12. Who should be contacted if the claim or authorization appears stalled?

Frequently asked questions

Does Medicare now cover GLP-1 drugs for weight loss?

The Medicare GLP-1 Bridge provides temporary access to certain included GLP-1 drugs for eligible Part D beneficiaries who meet the current criteria and use the medication for the covered weight-management purpose. It is not automatic coverage for every Medicare beneficiary or every GLP-1 product.

Is the Medicare GLP-1 Bridge copay always $50?

The Bridge copay is $50 for an approved monthly supply processed through the program. A consumer may still face separate costs for visits, tests, supplies, or services outside the medication claim.

Can Extra Help reduce the $50 copay?

No. CMS says the low-income subsidy does not reduce the Bridge copay because the demonstration operates outside the normal Part D benefit payment flow.

Does the $50 count toward my Part D out-of-pocket limit?

No. CMS says the copay does not count toward Part D true out-of-pocket costs or the Part D deductible.

Do I need a denial from my Part D plan first?

No. CMS says a Part D denial is not required before a potentially eligible claim is directed to the Medicare GLP-1 Bridge.

Can I apply directly without a provider?

No. A provider must prescribe an included medication and complete the required prior authorization when requested.

How quickly does prior authorization take?

CMS says the approval or denial is generally communicated within 72 hours after the completed prior-authorization submission. The pharmacy’s request may take an additional 24 to 72 hours to reach the provider after the initial claim is transmitted.

Does approval cover refills?

Current CMS guidance says an approval is valid through December 31, 2027 for refills and dose changes, unless the beneficiary changes to a different covered GLP-1 drug.

Where can I check whether I might qualify?

Use the official Medicare weight-loss drug eligibility tool or call 1-800-MEDICARE (1-800-633-4227). The tool is a screening resource; the provider and Bridge process make the actual coverage determination.

Next steps

Start with the official Medicare eligibility questions. Then gather the Medicare plan information, medication history, BMI record from treatment initiation, and relevant diagnoses before speaking with a licensed provider.

For broader context, review how online GLP-1 eligibility screening works, how online GLP-1 care works, and the GLP-1 pill versus injection comparison.

Important information

This guide explains public CMS program rules and is not medical, legal, insurance, or benefits advice. Coverage and eligibility can change. Verify current requirements with Medicare, the prescribing clinician, the pharmacy, and the applicable plan before making a treatment or payment decision.

Official sources

1. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge overview, last modified July 13, 2026.
2. Medicare.gov, Weight loss drugs and Medicare GLP-1 Bridge eligibility tool, accessed August 6, 2026.
3. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge information for providers, last modified July 13, 2026.
4. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge information for pharmacies, accessed August 6, 2026.
5. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge information for Part D plans, accessed August 6, 2026.